3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myeloid, Acute
34
Leukemia
26
Lymphoma, Non-Hodgkin
23
Lymphoma
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Recurrence
19
Leukemia, Lymphocytic, Chronic, B-Cell
19
Myelodysplastic Syndromes
18
Hematologic Neoplasms
18
Melanoma
16
Neoplasm Metastasis
15
Lymphoma, B-Cell
14
Multiple Myeloma
12
Pancreatic Neoplasms
11
Hodgkin Disease
11
Stomach Neoplasms
10
Ovarian Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
10
Breast Neoplasms
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Lymphoma, Mantle-Cell
7
Lymphoma, Follicular
7
Uterine Cervical Neoplasms
6
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
5
Neoplasms, Plasma Cell
5
Kidney Neoplasms
5
Burkitt Lymphoma
5
Myeloproliferative Disorders
4
Interventions
lutetium Lu 177 dotatate
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
pembrolizumab
1
olaparib
1
gallium Ga 68 dotatate
1
fludarabine
1
Surgical Procedures, Operative
1
Semaxinib
1
Radiosurgery
1
Proton Therapy
1
Nivolumab
1
Lysine
1
Ipilimumab
1
Interleukin-2
1
Imatinib Mesylate
1
Ga(III)-DOTATOC
1
Erlotinib Hydrochloride
1
Cyclophosphamide
1
Crossing Over, Genetic
1
CTLA-4 Antigen
1
Arginine
1
64Cu-SARTATE
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
177Lu-DOTA-JR11
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Meningioma
×
fludarabine
×
Clear all
NCT06640582
2024-11-05
BAH2472
Essen Biotech
Phase 1/2
Recruiting
85 enrolled